Beta Drugs Ltd.
•Add ratio to table
ABOUT
AI Sector View
AI GENERATEDHealthcare
This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.
PROS
- Company has a healthy return on capital (ROCE) of 22.9%
- Latest quarter profit grew 4156.8% YoY, showing strong momentum
- Company has delivered good sales growth of 27.5% CAGR over last 5 years
- Institutional investors have been accumulating - FII+DII up 6.1pp
- Company generates healthy free cash flow
CONS
- Promoter holding has decreased over last 2 years: -7.6pp
- A large part of profit comes from other income (29.7% of PBT)
- Total debt has risen sharply - up 2146.2% year on year
- Working capital days have increased from 122 to 303 days
- Stock is trading at 14.9x its book value
- Operating margins have contracted to 14.3% from 20.9%
* The pros and cons are machine generated based on quantitative rules.
Peer comparison
| Name | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | 1899.00 | 37.67 | 455633.71 | 0.84 | 2901.23 | 26.53 | 15299.88 | 10.98 | 19.11 | 28.81 |
| DIVISLAB | 9100.00 | 82.59 | 241576.41 | 0.33 | 902.00 | 65.50 | 3080.00 | 27.80 | 21.51 | 40.75 |
| TORNTPHARM | 4850.00 | 84.58 | 184478.41 | 0.78 | 566.00 | 3.28 | 4921.00 | 57.32 | 19.27 | 33.81 |
| CIPLA | 1385.00 | 33.19 | 111888.39 | 0.94 | 785.55 | -39.18 | 7119.28 | 4.13 | 16.00 | 16.73 |
| ZYDUSLIFE | 1121.00 | 24.78 | 111820.18 | 0.09 | 990.20 | -34.90 | 8017.00 | 23.97 | 21.39 | 24.54 |
| LAURUSLABS | 1840.00 | 90.93 | 99417.45 | 0.11 | 362.07 | 123.94 | 2026.31 | 29.10 | 18.20 | 31.50 |
| LUPIN | 2111.00 | 17.46 | 96528.82 | 0.85 | 1416.98 | 16.01 | 8276.89 | 34.28 | 28.86 | 29.59 |
| DRREDDY | 1154.00 | 29.89 | 96322.06 | 0.69 | 435.60 | -69.10 | 8099.80 | -5.21 | 13.75 | 10.63 |
| MANKIND | 2328.55 | 47.09 | 96179.61 | 0.04 | 574.09 | 29.12 | 4030.59 | 12.89 | 13.24 | 26.30 |
| AUROPHARMA | 1653.30 | 25.62 | 95127.23 | 0.24 | 1032.03 | 25.22 | 9150.35 | 17.44 | 12.76 | 20.54 |
| GLENMARK | 2427.00 | 38.10 | 68495.93 | 0.10 | 482.83 | 927.88 | 4018.48 | 31.35 | 20.35 | 20.03 |
| BETA | 2218.50 | 59.48 | 2467.25 | 0.00 | 164.86 | 1724.88 | 1255.50 | 1239.00 | 25.23 | 21.80 |
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
| Dec 2024 | Mar 2025 | Jun 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|
| 48 | 54 | 66 | 50 | 54 | 558 | |
| 43 | 53 | 64 | 44 | 45 | 498 | |
| Operating Profit | 6 | 0 | 3 | 7 | 10 | 61 |
| OPM % | 11.87% | 0.57% | 4.05% | 13.03% | 17.96% | 10.87% |
| -1 | 6 | 3 | 3 | 3 | 19 | |
| Interest | 1 | 3 | 3 | 3 | 3 | 16 |
| Depreciation | 2 | 2 | 2 | 3 | 3 | 25 |
| Profit before Tax | 1 | 2 | 6 | 3 | 7 | 79 |
| Tax % | 25.00% | 30.63% | 25.17% | 3.56% | 24.50% | 25.25% |
| Net Profit | 1 | 1 | 4 | 3 | 5 | 59 |
| 0.78 | 1.38 | 4.19 | 3.21 | 5.26 | 5.55 |
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 42 | 51 | 58 | 65 | 79 | 125 | 158 | 198 | 220 | 227 | |
| 23 | 34 | 41 | 48 | 54 | 64 | 100 | 127 | 164 | 189 | 202 | |
| Operating Profit | 3 | 7 | 9 | 10 | 12 | 15 | 25 | 31 | 34 | 31 | 25 |
| OPM % | 11.44% | 17.48% | 18.70% | 17.76% | 17.99% | 19.27% | 20.17% | 19.76% | 16.96% | 14.27% | 11.05% |
| 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 2 | 2 | 10 | |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 5 | 10 |
| Depreciation | 1 | 1 | 2 | 2 | 3 | 5 | 5 | 6 | 5 | 7 | 10 |
| Profit before Tax | 1 | 5 | 7 | 7 | 9 | 10 | 20 | 25 | 29 | 21 | 24 |
| Tax % | 0.00% | 18.70% | 1.05% | -3.32% | 20.67% | 29.38% | 29.34% | 25.36% | 25.60% | 25.95% | 21.97% |
| Net Profit | 1 | 4 | 7 | 8 | 7 | 7 | 14 | 19 | 22 | 15 | 19 |
| EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7.26 | 14.82 | 19.57 | 22.82 | 15.29 | — |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
COMPOUNDED SALES GROWTH
- 10 Years:
- 96%
- 5 Years:
- 28%
- 3 Years:
- 21%
COMPOUNDED PROFIT GROWTH
- 10 Years:
- —
- 5 Years:
- 17%
- 3 Years:
- 3%
STOCK PRICE CAGR
- 10 Years:
- —
- 5 Years:
- 45%
- 3 Years:
- 33%
- 1 Year:
- 18%
RETURN ON EQUITY
- 10 Years:
- 33%
- 5 Years:
- 17%
- 3 Years:
- 18%
- Last Year:
- 13%
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 1 | 1 | 9 | 9 | 10 | 10 | 10 | 10 | 10 | 10 |
| 1 | 5 | 24 | 32 | 47 | 54 | 68 | 87 | 106 | 119 | |
| 8 | 8 | 9 | 9 | 9 | 6 | 9 | 8 | 8 | 128 | |
| Trade Payables | 4 | 7 | 6 | 10 | 9 | 13 | 20 | 23 | 36 | 41 |
| 1 | 2 | 2 | 6 | 8 | 6 | 9 | 10 | 15 | 23 | |
| Total Liabilities | 15 | 23 | 50 | 66 | 83 | 89 | 115 | 137 | 175 | 321 |
| 7 | 8 | 13 | 12 | 32 | 28 | 34 | 35 | 36 | 53 | |
| Capital Work in Progress | 0 | 0 | 1 | 15 | 0 | 2 | 0 | 0 | 0 | 0 |
| 0 | 0 | 0 | 2 | 6 | 7 | 7 | 7 | 6 | 6 | |
| 3 | 2 | 3 | 6 | 6 | 8 | 8 | 14 | 22 | 27 | |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 50 | 49 | |
| Cash & Bank | 0 | 0 | 12 | 3 | 4 | 8 | 16 | 18 | 27 | 142 |
| 5 | 13 | 20 | 28 | 35 | 36 | 50 | 64 | 33 | 44 | |
| Total Assets | 15 | 23 | 50 | 66 | 83 | 89 | 115 | 137 | 175 | 321 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0 | 5 | 17 | 8 | 6 | 12 | 19 | 10 | 21 | 18 | |
| Cash from Investing | -2 | -2 | -11 | -16 | -14 | -3 | -13 | -6 | -11 | -21 |
| Cash from Financing | 3 | -3 | 5 | -1 | 9 | -4 | 1 | -2 | -1 | 118 |
| 0 | 0 | 12 | -9 | 1 | 4 | 7 | 2 | 9 | 115 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| PER SHARE | ||||||||||
| EPS (₹) | 11.23 | 42.27 | 7.82 | 8.92 | 7.39 | 7.26 | 14.82 | 19.57 | 22.82 | 15.29 |
| Book Value (₹) | 21.79 | 60.11 | 38.02 | 46.93 | 58.71 | 65.96 | 80.57 | 100.12 | 120.67 | 127.83 |
| Dividend per Share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash EPS (₹) | 3.79 | 8.80 | 9.49 | 11.16 | 9.59 | 12.13 | 19.53 | 24.78 | 26.41 | 22.66 |
| PROFITABILITY | ||||||||||
| Operating Margin % | 11.50% | 17.55% | 19.18% | 18.30% | 18.63% | 20.04% | 20.86% | 20.42% | 16.96% | 14.27% |
| Net Margin % | 4.30% | 10.25% | 13.38% | 13.29% | 10.87% | 8.78% | 11.41% | 11.92% | 11.10% | 7.01% |
| ROE % | 69.39% | 103.22% | 34.73% | 21.00% | 14.63% | 11.64% | 20.23% | 21.66% | 20.67% | 12.60% |
| ROCE % | 21.92% | 48.91% | 28.63% | 18.42% | 16.85% | 15.91% | 26.91% | 27.93% | 27.27% | 13.53% |
| 9.77% | 22.23% | 18.58% | 13.41% | 9.54% | 8.12% | 14.03% | 14.97% | 14.06% | 6.21% | |
| EFFICIENCY | ||||||||||
| Debtor Days | 31 | 65 | 90 | 100 | 107 | 96 | 76 | 87 | 87 | 82 |
| Inventory Days | 29 | 23 | 19 | 29 | 35 | 32 | 24 | 26 | 33 | 41 |
| Payable Days | 75 | 85 | 88 | 98 | 102 | 95 | 85 | 94 | 96 | 116 |
| -15 | 3 | 20 | 31 | 40 | 33 | 15 | 18 | 24 | 7 | |
| FINANCIAL HEALTH | ||||||||||
| Debt to Equity (x) | 3.79x | 1.35x | 0.23x | 0.19x | 0.16x | 0.08x | 0.09x | 0.06x | 0.05x | 0.99x |
| Interest Coverage (x) | 2.71x | 7.40x | 7.74x | 11.18x | 14.98x | 13.79x | 49.91x | 31.13x | 29.15x | 5.38x |
| 0.86x | 1.16x | 2.39x | 1.66x | 1.70x | 2.28x | 2.23x | 2.52x | 2.24x | 3.88x | |
| GROWTH | ||||||||||
| Revenue Growth % | 9963.79% | 57.91% | 21.40% | 14.80% | 12.53% | 21.64% | 57.13% | 26.45% | 25.18% | 11.43% |
| Operating Profit Growth % | 0.00% | 140.90% | 32.70% | 9.51% | 14.54% | 30.85% | 63.57% | 23.81% | 9.35% | 6.67% |
| Net Profit Growth % | 1093.78% | 276.51% | 58.43% | 14.05% | -7.96% | -1.72% | 104.17% | 32.08% | 16.58% | -29.65% |
| 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 16.58% | -33.00% | |
| VALUATION | ||||||||||
| P/E (x) | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 51.49x | 124.64x |
| P/B (x) | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 10.22x | 14.91x |
| Dividend Yield % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 33.03x | 50.76x |
Documents
Corporate disclosures, annual reports, credit ratings, and concall transcripts
2026-09-05 - Beta Drugs Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 30, 2026
2026-09-03 - Beta Drugs Limited has informed the Exchange about 'Beta Drugs Limited has informed the Exchange that Register of Members & Share Transfer Books of the Company will remain closed from 24-Sep-2026 to 30-Sep-2026 for the purpose of ANNUAL GENERAL MEETING to be held on 30.09.2026
2026-09-03 - Beta Drugs Limited has informed the Exchange regarding Notice of undefined to be held on September 30, 2026
2026-09-03 - Beta Drugs Limited has informed the Exchange regarding Outcome of Board Meeting held on September 03, 2026.
2026-08-18 - Beta Drugs Limited has informed the Exchange regarding Outcome of Board Meeting held on August 18, 2026.
2026-08-14 - Monitoring Agency Report for the Quarter ended 30th June, 2026
2026-07-27 - Beta Drugs Limited has informed the Exchange about Investor Presentation
2026-07-23 - The Exchange had sought clarification from Beta Drugs Limited for the quarter ended 30-Jun-2026 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company was required to clarify the following: The response of the Company is enclosed.
2026-07-22 - The Exchange has sought clarification from Beta Drugs Limited for the quarter ended 30-Jun-2026 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: The response of the Company is awaited.
News
Recent coverage and analyst commentary for BETA
Loading news…
AI Stock Analyst
Beta Drugs Ltd.
Sign in to Chat with AI
Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.
✨ Sign In to ChatFree 5nance Account